BWA
OCUL icon

Basecamp Wealth Advisors’s Ocular Therapeutix OCUL Stock Holding History

Basecamp Wealth Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$972 Buy
99
+53
+115% +$480 ﹤0.01% 1528
2026
Q1 		$390 Buy
+46
New +$438 ﹤0.01% 1776

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Basecamp Wealth Advisors's OCUL Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Ocular Therapeutix (OCUL) stake by 115% in Q2 2026, buying an estimated $480 and bringing the position to 99 shares worth $972. The position accounts for ﹤0.01% of the portfolio, ranked #1528.

Basecamp Wealth Advisors first reported a position in OCUL in Q1 2026 and has held it in 2 quarters since. 261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Basecamp Wealth Advisors held 99 shares of Ocular Therapeutix worth $972 as of Q2 2026.
  • Basecamp Wealth Advisors bought 53 Ocular Therapeutix shares in Q2 2026, an estimated $480.
  • Ocular Therapeutix made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1528 holding.
  • Basecamp Wealth Advisors first reported a position in Ocular Therapeutix in Q1 2026 and has held it in 2 quarters since.
  • 261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.